Newly diagnosed patients with type 2 diabetes mellitus (T2DM) should be offered a sodium–glucose co-transporter-2 (SGLT-2) inhibitor – which include dapagliflozin and empagliflozin – earlier in their treatment alongside metformin,…
The IndependentNew diabetes drug could revolutionize care for thousandsA new class of once-daily tablets, SGLT-2 inhibitors, has been found to significantly reduce premature deaths in type 2 diabetes patients..2 hours…
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it’s…
Initiating treatment with a sodium–glucose cotransporter-2 (SGLT2) inhibitor rather than a glucagon-like peptide-1 receptor agonist (GLP-1RA) is associated with better renal outcomes in people with type 2 diabetes, according to…
CureusEffects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Lipid Profiles in Type 2 Diabetes: A Systematic ReviewSodium glucose cotransporter 2 (SGLT2) inhibitors provide cardiometabolic benefits in adults with type…
CureusComparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisSodium-glucose cotransporter-2 (SGLT2) inhibitors…
Credit: Pixabay/CC0 Public Domain A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have a slightly lower risk of…
The Cureus Journal of Medical ScienceSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSodium-glucose cotransporter-2 (SGLT2)…
The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2…
A large cohort study found three popular GLP-1-based diabetes drugs — semaglutide, dulaglutide, and tirzepatide — carry similar risks for serious adverse GI events, with a rate of about 12…